Positive interim data announced in phase 1/2 trial of gene therapy for Canavan disease
Myrtelle Inc. announced updated findings of the open-label phase 1/2 clinical trial of its recombinant adeno-associated virus vector-based investigational gene therapy for Canavan disease, a fatal genetic disorder in children.According to a release from Myrtelle, early data from the first in-human study, which is being conducted at Dayton Children’s Hospital in Ohio, revealed that all eight
Source: healio.com